Technology and Heart Failure Therapeutics (THT 2024)

Technology and Heart Failure Therapeutics (THT 2024) is organized by CardioVascular Research Foundation (CRF) and will be held from Mar 04 - 06, 2024 at Weston Boston Seaport, Boston, Massachusetts, United States of America.

Professional Practice Gap and Educational Need:
Given the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart failure.

Technology and Heart Failure Therapeutics (THT) 2024 is the conference that focuses on device- and technology-based treatments, while putting these into the perspective of drug-based therapies, thus filling existing gaps.

Covering a full range of updates on the current status of drug- and device-based treatments for heart failure across the spectrum, LV ejection fractions, and late-breaking pivotal studies that have not yet appeared in publications or in treatment guidelines, THT 2024 is an immersive experience in the latest innovations that practitioners can put into practice for treating heart failure.

Concomitantly, with unlimited opportunities for learning and global engagement, THT 2024 offers a future-oriented view of the pipeline for heart failure therapeutics, with a focus on technologies (drugs, devices, monitoring strategies) that are currently in development and in clinical trials — as well as an overview of the rapid advances in artificial intelligence and machine learning and how these technologies will transform the care of heart failure patients in the near future.

Learning Objectives:
By the end of this course, attendees should be able to:
• Recount an up-to-date review of the current standards for the care of patients with heart failure across the spectrum of ejection fractions, etiologies and disease severities.
• Understand the results of recently conducted studies of heart failure therapies (devices and drugs) that have not yet been incorporated into heart failure guidelines.
• Understand the different types of monitoring and therapeutic devices that are currently under development for patients with acute and chronic heart failure and the status of ongoing clinical trials.
• Understand how big data, artificial intelligence, machine learning and data-security matters are being incorporated into the management of heart failure patients.

What's New at THT 2024:
• Expanded presentations and discussions about unusual and complex cases.
• Deeper dive into regulatory aspects of new devices, including interactive discussions with FDA representatives.
• More multilayered discussions about controversies surrounding clinical trials of cardiogenic shock.
• Topical sessions that ignite deep discussion on long-standing electrophysiology-based treatments for heart failure — reopening the conversation on relevancy of these long-standing standard treatments in the modern era of medical therapy.
• Deep discussions on how to treat atrial fibrillation in HFrEF and HFpEF patients.